GLIVEC 100 mg, film-coated tablet 60 tablets
Active ingredients: Imatinib mesylate, Imatinib
Commercialized according to BDPMDispensing in France: Prescription only
Film-coated tablet60 tabletsorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- GLIVEC 100 mg, comprimé pelliculé
- Pharmaceutical form
- comprimé pelliculé
- Route of administration
- orale
- Presentation description
- plaquette(s) thermoformée(s) PVDC aluminium de 60 comprimé(s)
- Marketing authorisation holder
- NOVARTIS EUROPHARM (IRLANDE)
- Reimbursement according to BDPM
- 100 %
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 1 Mar 2021
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Initial prescription by a hospital doctor
- Prescribed by specialists only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
64936439CIP73018721CIP133400930187210Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| IMATINIB BASEcomprimé | 100 mg · un comprimé | FT |
| IMATINIB (MÉSILATE D')comprimé | 119,5 mg · un comprimé | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.